Abstract. Obesity is a risk factor for several pain syndromes and is associated with increased pain sensitivity. Evidence suggests that obesity causes the downregulation of peroxisome proliferator-activated receptor (PPAR)α in the spinal cord, contributing to augmented peripheral edema and inflammatory hyperalgesia. Ursolic acid (UA), a natural pentacyclic triterpenoid carboxylic acid, has been shown to upregulate PPARα in the peripheral tissues of obese animals. The present study hypothesized that UA prevents augmented peripheral inflammation and inflammatory hyperalgesia in obesity by restoring downregulated spinal PPARα. The present study demonstrated that Sprague-Dawley rats fed a high-fat diet (HFD) for 12 weeks developed obesity and metabolic disorder. Following carrageenan injection, the HFD rats exhibited increased thermal hyperalgesia and paw edema, compared with the rats fed a low-fat diet. Molecular investigations revealed that the HFD rats exhibited decreased PPARα activity, and exaggerated expression of inflammatory mediators and nuclear factor-kB activity in the spinal cord in response to carrageenan. Oral administration of UA ameliorated obesity and metabolic disorder, and prevented increased thermal hyperalgesia and paw edema in the HFD rats. Additionally, UA normalized PPARα activity and inhibited the exaggerated spinal cord inflammatory response to carrageenan. Although the knockdown of spinal PPARα with small interfering RNA following the administration of UA did not alter obesity or metabolic parameters, it eradicated the beneficial effects of UA on thermal hyperalgesia and paw edema, and reversed the spinal cord inflammatory response. These results suggested that the systemic administration of UA inhibited the exaggerated spinal cord inflammatory response to peripheral inflammatory stimulation in HFD-induced obesity by restoring downregulated spinal PPARα, preventing peripheral inflammation and inflammatory hyperalgesia. UA may be a potential therapeutic option for the prevention of increased inflammatory pain in obese patients.
Introduction
The rise in global obesity rates over the last three decades has been substantial and widespread, becoming a major public health epidemic in developed and developing countries (1) (2) (3) . Obesity is also well-recognized as a risk factor associated with multiple pain syndromes, including lower back pain, tension-type headaches and migraines, fibromyalgia, abdominal pain and chronic widespread pain (4-7). These pain conditions are not solely due to mechanical stress on the joints due to increased load, other factors have been suggested to be involved in the progression of chronic pain in obesity.
Evidence from experimental studies has demonstrated that obesity is associated with increased peripheral inflammation and pain sensitivity in response to inflammatory stimulation (8) (9) (10) . The spinal cord is the predominant relay station in the neural communication between inflamed areas and the central nervous system (CNS) (11) . Obesity has been shown to induce the downregulation of spinal peroxisome proliferator-activated receptor (PPAR)α, which sensitizes peripheral inflammatory stimulation by increasing the inflammatory response in the spinal cord, contributing to augmented peripheral inflammation and inflammatory hyperalgesia (12) . Thus, upregulating PPARα in the spinal cord may offer a novel therapeutic strategy for preventing augmented peripheral inflammation and inflammatory hyperalgesia in obesity.
Ursolic acid (UA), a natural pentacyclic triterpenoid carboxylic acid, is the major component of several traditional medicine herbs and has multiple biological activities, including the regulation of lipid and glucose metabolism (13, 14) , in addition to anti-oxidative, antimutagenic, anticarcinogenic, antimicrobial and anti-atherosclerotic effects (15) (16) (17) . UA also exhibits analgesic and anti-inflammatory activities in normal animals (18, 19) , however, the molecular mechanism, and whether UA has beneficial effects on inflammatory Ursolic acid prevents augmented peripheral inflammation and inflammatory hyperalgesia in high-fat diet-induced obese rats by restoring downregulated spinal PPARα hyperalgesia in obesity remain to be elucidated. Previous studies have demonstrated that UA increases the expression and activity of PPARα in the liver of obese animals (13, 14) , and UA has been shown to cross the blood brain barrier (20, 21) . The present study was performed to test the hypothesis that UA prevents increased peripheral inflammation and inflammatory hyperalgesia in obesity by restoring downregulated spinal PPARα. For this purpose, a diet-induced rat model of obesity was used, which has been considered to be the most relevant model with regard to human obesity (22) .
Materials and methods
Animals. Adult male Sprague-Dawley rats weighing 85±3 g were purchased from the Beijing Laboratory Animal Research Center (Beijing, China). They were housed in a room maintained at 23-25˚C on a 12-h-light/dark cycle, and were provided with rat chow and water ad libitum. The study was approved by the ethics committee of Shandong University (Shandong, China), and all animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of Shandong University.
Experimental protocol. Following 1 week of adaptation to their housing environment, the rats were randomly divided into the following groups (n=18 in each group): i) High-fat diet (HFD) control group, comprising HFD-fed rats without treatment; ii) HFD+UA (Sigma-Aldrich, St. Louis, MO, USA), comprising HFD-fed rats treated with UA; iii) HFD+UA+PPARα small interfering (si)RNA, comprising HFD-fed rats treated with UA and PPARα siRNA; iv) HFD+UA+scrambled siRNA, comprising HFD-fed rats treated with UA and scrambled siRNA; v) low-fat diet (LFD), comprising LFD-fed rats without treatment. The rats, which were assigned to the HFD or LFD groups were fed a HFD (45% kcal as fat; Research Diets, New Brunswick, NJ, USA) or a LFD (10% kcal as fat) for 12 weeks, respectively. UA (250 mg/kg/day) was orally administered for 8 weeks, starting from week 4, when the HFD-fed rats had become significantly heavier, compared with the LFD-fed rats (12) . The dose of UA was based on a previous study (14) . PPARα siRNA (2 µg/10 µl) or scrambled siRNA was intrathecally injected at 10 weeks, as previously described (12) . Body weights were measured weekly. At the end of the experiments, 12 weeks post-HFD or LFD feeding), six rats from each group were sacrificed by decapitation using a guillotine (Kent Scientific Corporation, Torrington, CT, USA) and 5-ml blood samples were collected for the measurement of metabolic parameters, and the spinal cord was removed for assessment of the expression levels of PPARα and inflammatory mediators, and the activity of nuclear factor (NF)-κB at baseline. Other rats (n=12 rats in each group) received a subcutaneous injection of 3% carrageenan (50 µl; Sigma-Aldrich) into the mid-plantar region of the right hindpaw, as previously described (12) . The thermal and mechanical responses of the right hindpaw, and the paw volumes of the right and left hindpaws were then measured at baseline, and at 2, 4, 6, 8 and 24 h following carrageenan injection. At 6 h post-carrageenan injection, six rats from each group were sacrificed by decapitation using a guillotine to assess the expression levels of PPARα and inflammatory mediators, and the activity of NF-κB in the spinal cord in response to carrageenan injection. The remaining rats were sacrificed 24 h after carrageenan injection by decapitation using a guillotine.
Intrathecal injection of siRNA. PPARα siRNA (Shanghai GenePharma Co., Ltd., Shanghai, China) was constructed using IMG-800 vector (pSuppressorNeo; Imgenex, San Diego, CA, USA), as previously described (12) . The siRNA target sequence used for the construction of the PPARα plasmid vector was: 5'-TCG AGT GTG ATC GAA GCT GCA AGA TGG AAT TCG ATC TTG CAG CTT CGA TCA CAC TTTTT-3'. The PPARα siRNA or scrambled siRNA (Shanghai GenePharma) was suspended in serum-free media and intrathecally injected in a volume of 10 µl using a 25-µl Hamilton microsyringe (Hamilton Co., Reno, NV, USA) fitted with a 27-gauge needle. The needle was inserted into the subarachnoid space through the intervertebral foramen. The correct placement of the needle was verified by a tail or foot flick response.
Hindpaw withdrawal responses to thermal and mechanical stimulation. Prior to the assessment of response to thermal and mechanical stimulation, the animals underwent acclimatization to the assessment environment for 1 week by placing them in the thermal and mechanical assessment boxes for 30-60 min twice daily. The hindpaw withdrawal responses to thermal stimulation were assessed using a plantar test instrument (#7370; Ugo Basile; Comerio, VA, Italy), as previously described (12) . The thermal stimulation was performed using an infrared beam, which was directed onto the plantar surface of the hindpaw, and the latency to paw withdrawal was recorded. At each time point (0, 2, 4, 6, 8 and 24 h after the carrageenan injection), three measurements were performed and the average value was calculated. A cut-off value of 25 sec was applied in the absence of a response to prevent tissue damage. The hindpaw withdrawal responses to mechanical stimulation were assessed using a dynamic plantar esthesiometer (# 37400; Ugo Basile), which consisted of a filament, which touched the plantar surface of the hindpaw and began to exert an upwards force until the paw was withdrawn. A cut-off of 50 g was applied to prevent tissue damage.
Assessment of paw edema. Paw edema was measured using a plethysmometer (#7140; Ugo Basile), as described previously (12) . The paw volume was determined based on the displacement of water when the paw was submerged into the water. The volumes of the left and the right paws were measured, and the changes in paw volume were calculated as the percentage difference in volume between the ipsilateral and contralateral paw.
Western blot analysis. Nuclear and cytoplasmic fractions were extracted from the spinal cord using a Nuclear Extract kit (cat. no. 40010; Active Motif, Carlsbad, CA, USA). For the assessment of inflammatory mediators, protein was isolated from the spinal cord using cell lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA-Na 2 , 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 and 1 µg/ml leupeptin; Cell Signaling Technology, Inc., Beverly, MA, USA). The protein concen-tration was determined by a Bradford assay (Bio-Rad Labs Informatics Division, Philadelphia, PA, USA). Briefly, dye reagent was prepared (dilution, 1 part dye reagent concentrate with 4 part double-distilled water). The bovine serum albumin (BSA) protein standard was prepared by making serial dilutions from a stock solution. 10 µl BSA protein standards and samples were added and a blank of double-distilled water was used. After incubation for 5 min at room temperature, the absorbance was measured at 595 nm on a microplate reader (EL311S; Bio-Tek Instruments, Winooski, VT, USA). The optical density readings were taken and a standard curve was generated. The concentrations of samples were obtained based on the standard curve.
Nuclear protein levels of PPARα and NF-κB p65, protein levels of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS), and cytoplasmic protein levels of inhibitor of NF-κBα (IκBα), were detected using western blot analysis. Briefly, 20 µg protein was loaded onto 10% SDS-polyacrylamide gel (Bio-Rad Labs Informatics Division). Following electrophoresis (200 V for 35 min), proteins were transferred to a polyvinylidene fluoride membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membrane was blocked with Tris-buffered saline and Tween-20 (Bio-Rad Labs Informatics Division) with 5% skimmed milk, and incubated overnight at 4˚C with the following primary antibodies (all purchased from Santa Cruz Biotechnology, Inc., Dallas, TX, USA): Rabbit polyclonal anti-human IL-1β (cat. no. sc-7884; 1:200); goat polyclonal anti-human TNF-α (cat. no. sc-1350; 1:400); goat polyclonal anti-human COX-2 (cat.
no. sc-23983; 1:400); rabbit polyclonal anti-mouse iNOS (cat. no. sc-650; 1:200); rabbit polyclonal anti-human NF-κB p65 (cat. no. sc-109; 1:200); rabbit polyclonal anti-human IκBα (cat. no. sc-847; 1:300); rabbit polyclonal anti-human PPAR-α (cat. no. sc-9000; 1:200); and goat polyclonal anti-human β-actin (cat. no. sc-1615; 1:1,000). After washing three times, the membrane was incubated for 1 h at room temperature with the following secondary antibodies (all purchased from Santa Cruz Biotechnology, Inc.): Goat anti-rabbit horseradish peroxidase conjugated secondary antibody (cat. no. sc-2030; 1:5,000) or donkey anti-goat horseradish peroxidase conjugated secondary antibody (cat. no. sc-2020; 1:5,000). After washing three times, the signals of the detected proteins were visualized using an enhanced chemiluminescence reaction system (EMD Millipore, Billerica, MA, USA). The density of the bands was analyzed using National Institutes of Health ImageJ software (version 1.48; NIH, Bethesda, MD, USA) and all data were normalized to β-actin.
PPARα and NF-κB p65 activity. The DNA binding activity of PPARα and NF-κB p65 in the spinal nuclear extraction were measured using Transcription Factor Assay kits (cat. no. ab13112; Abcam, Cambridge, MA, USA and Active Motif), according to the manufacturer's protocols.
Biochemical measurements. Whole blood samples were centrifuged at 2,100 x g for 15 min at 4˚C and the plasma from each blood sample was collected. The plasma levels of glucose, total cholesterol and triglyceride were measured using a Roche Hitachi 911 Chemistry Analyzer (Hitachi Inc., Statistical analysis. GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA) was used for data analysis. Data are presented as the mean ± standard error of the mean. The differences between groups were analyzed by two-way analysis of variance, followed by Bonferroni post-hoc tests for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.
Results

Effects of UA on body weight and metabolic parameters.
As shown in Fig. 1 , body weights were significantly higher throughout the investigation in all HFD groups, compared with those in the LFD group, beginning at week 4. No differences in body weight were observed among the four HFD groups at 4 weeks. Compared with the HFD control rats, the HFD+UA rats exhibited significantly reduced body weight gain at 12 weeks. The intrathecal injections of PPARα siRNA or scrambled siRNA had no effects on body weight gain in the HFD+UA rats.
At 12 weeks, the plasma levels of insulin, leptin and cholesterol were higher, and the plasma levels of adiponectin were lower in the HFD control rats, compared with those in the LFD rats. Compared with the HFD control rats, the HFD+UA rats exhibited significant improvements in all the above parameters. The intrathecal injections of PPARα siRNA and scrambled siRNA did not alter these metabolic parameters in the HFD+UA rats. No differences in the plasma levels of glucose or triglycerides were observed between the experimental groups.
Effects of UA on thermal and mechanical hyperalgesia and paw edema. No differences were observed in thermal hyperalgesia, mechanical allodynia or paw edema between the experimental groups at baseline (prior to carrageenan injection), as shown in Fig. 2 . Following carrageenan injection, all groups of rats exhibited significant thermal hyperalgesia, mechanical allodynia and paw edema in the injected paw. The maximum decreases in thermal response latency and mechanical response threshold, and maximum increase in paw volume, were observed in the carrageenan-injected paw at 6 h in the LFD rats, but at 4 h in the HFD control rats. Compared with the LFD rats, the HFD control rats had more pronounced thermal hyperalgesia between 4 and 8 h following carrageenan injection ( Fig. 2A) . Compared with the HFD control rats, the HFD+UA rats exhibited significantly attenuated thermal hyperalgesia. Of note, the intrathecal injection of PPARα siRNA, but not of scrambled siRNA, completely eliminated the beneficial effect of UA on thermal hyperalgesia in the HFD+UA rats in response to carrageenan injection. No significant differences were observed in the mechanical response thresholds between the experimental groups throughout the experimental period (Fig. 2B) . Compared with the LFD rats, 
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the HFD control rats exhibited increased paw edema between 2 and 24 h following carrageenan injection (Fig. 2C) . The HFD+UA rats exhibited significantly reduced paw edema, compared with the HFD control rats. The improvement in paw edema observed in the HFD+UA rats was completely abrogated by the intrathecal injection of PPARα siRNA, but not scrambled siRNA.
Effects of UA on the inflammatory response in the spinal cord.
As the inflammatory response in the spinal cord has been shown to be associated with peripheral inflammation and pain sensitivity, the present study examined the effect of systemic administration of UA on the expression levels of inflammatory mediators and activation of NF-kB, a key mediator of inflammation, in the spinal cord at baseline and 6 h post-carrageenan injection. The UA, ursolic acid; HFD, high-fat diet; LFD, low-fat diet; CAR, carrageenan; Sc, scrambled; siRNA, small interfering RNA; NF-κB, nuclear factor-κB; PPARα, peroxisome proliferator-activated receptor α; IκBα, inhibitor of NF-κB; OD, optical density.
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time points selected were based on previous studies showing that the acute phase of the inflammatory response and hyperalgesia (0-6 h) is characterized by central sensitization, mediated predominantly by prostanoids, the products of COX-2 (11, 23) .
No differences were observed in the expression levels of the IL-1β, TNF-α, COX-2 or iNOS inflammatory mediators (Fig. 3) , the activity of NF-κB p65 or the expression of IκBα (Fig. 4) in the spinal cord between the experimental groups at baseline. At 6 h post-carrageenan injection, all groups of rats exhibited markedly increased expression levels of inflammatory mediators, augmented expression and activity of NF-κB p65, and reduced expression of IκBα in the spinal cord, compared with respective baseline values. Notably, the HFD control rats exhibited a more pronounced inflammatory response, which was prevented in the HFD+UA rats. The decreased inflammatory response in the spinal cord of the HFD+UA rats was reversed by intrathecal injection of PPARα siRNA, but not scrambled siRNA.
Effects of UA on the expression and activity of PPARα in the spinal cord.
To further investigate the molecular mechanisms by which UA attenuates exaggerated inflammatory response in the spinal cord, and prevents augmented peripheral inflammation and inflammatory hyperalgesia in obesity, the present study measured the expression and activity of PPARα in the spinal cord.
At 12 weeks, the HFD control rats exhibited significant decreases in the expression and activity of PPARα at baseline, compared with the LFD rats (Fig. 5) . Of note, the decreases in the spinal expression and activity of PPARα were normalized in the HFD+UA rats. However, intrathecal injection of PPARα siRNA in the HFD+UA rats reduced the spinal expression and activity of PPARα to the same extent as in the HFD control rats. Intrathecal injection of scrambled siRNA in the HFD+UA rats had no effects on the expression and activity of PPARα.
Carrageenan injection caused significant reductions in the spinal expression and activity of PPARα in all groups, compared with their baseline values. Of note, the spinal expression and activity of PPARα remained significantly higher in the LFD rats, HFD+UA rats and HFD+UA rats treated with scrambled siRNA, compared with the other two groups.
Discussion
The present study reported the novel finding that the systemic administration of UA restored the HFD-induced downregulation of spinal PPARα, which resulted in inhibition of the exaggerated expression of inflammatory mediators in the spinal cord in response to peripheral inflammatory challenge, and the prevention of augmented peripheral pain sensitivity and paw edema in the HFD-induced obese rats. To the best of our knowledge, the present study is the first to report that UA exerted beneficial effects on peripheral inflammation and inflammatory hyperalgesia in obesity via the activation of PPARα in the spinal cord.
Inflammatory mediators in the CNS have been implicated in the pathogenesis of peripheral inflammation and inflammatory hyperalgesia (10) . Peripheral injury induces the increased expression of central inflammatory mediators, particularly COX-2 and iNOS, which are involved in inflammatory signaling to the CNS (11, 24, 25) . Increased expression of COX-2 in the CNS promotes the synthesis and release of prostaglandin E2, contributing to the severity of the inflammatory and peripheral pain responses (24) . Carrageenan injection in the paws of rodents can rapidly induce the expression of the proinflammatory cytokines, COX-2 and iNOS, in the spinal cord and other regions of the CNS (24) . Emerging evidence suggests that the expression levels of inflammatory mediators in the CNS in response to peripheral inflammatory challenge can be mediated by PPARα, a ligand-activated transcription factor which belongs to the nuclear receptor superfamily (26) and is expressed in the CNS, including the brain and spinal cord (11, 23, 27) . PPARα is important in regulating lipid metabolism and adipocyte differentiation (28, 29) . In addi- 
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tion, PPARα is crucial in the regulation of inflammatory responses (30, 31) . Previous experimental investigation has demonstrated that HFD-induced obesity causes decreases in the expression and activity of PPARy in the spinal cord, which results in the exaggerated expression of inflammatory mediators in response to carrageenan injection in the paw, contributing to augmented peripheral inflammation and inflammatory hyperalgesia (12) . UA, a natural pentacyclic triterpenoid and a major bioactive compound in several medicinal herbs, has been shown to increase the expression of PPARα in the liver in obese animals (14) . UA also crosses the blood brain barrier (20, 21) . In the present study, it was found that the systemic administration of UA for 8 weeks, commencing following a 4-week-period of feeding with a HFD, significantly prevented the carrageenan-induced augmentation of peripheral inflammation and inflammatory hyperalgesia in obese rats, as evidenced by reduced paw edema and increased thermal latency. Molecular investigations revealed that UA restored obesity-induced reductions in the baseline expression and activity of PPARα in the spinal cord, which led to decreased expression levels of inflammatory mediators and the activity of NF-kB in response to peripheral carrageenan injection. Notably, the expression levels of inflammatory mediators in the spinal cord at baseline were similar among the groups, although the baseline expression and activity of PPARα were decreased in the HFD control rats, and were normalized in the HFD+UA rats. Following carrageenan injection, the expression levels of inflammatory mediators in the spinal cord were significantly higher in the HFD control rats, compared with the LFD rats, but were attenuated in the HFD+UA rats. These observations suggested that changes in the spinal expression and activity of PPARα may not affect the expression of inflammatory mediators under normal conditions. However, the decreased spinal expression and activity of PPARα at baseline may increase susceptibility to peripheral inflammatory stimulation, causing an exaggerated inflammatory response in the spinal cord. In the present study, it was observed that the abnormal metabolic parameters in obese rats were ameliorated by the systemic administration of UA. These results are consistent with findings of others that UA improves metabolic disorders in HFD-induced obese animals (13, 14) . However, the restoration of spinal PPARα by UA may not be entirely attributed to improvement in metabolic disorders, as UA partially improved, but did not normalize, the metabolic parameters in the obese animals. Furthermore, knockdown of spinal PPARα in the HFD+UA rats by the intrathecal injection of PPARα siRNA did not alter the UA-induced improvement in metabolic parameters, but reversed the UA-induced decrease in the expression levels of spinal inflammatory mediators, and eliminated the beneficial effects of UA on peripheral inflammation and inflammatory hyperalgesia. These results indicated that the systemic administration of UA inhibited the exaggerated inflammatory responses in the spinal cord in response to peripheral inflammatory stimulation by upregulating spinal PPARα, thereby preventing augmented peripheral inflammation and inflammatory hyperalgesia.
PPARα has been suggested to control inflammatory gene expression by modulating the activity of the NF-κB transcription factor. The expression of a variety of inflammatory genes is driven by NF-κB, the transcriptional activity of which is regulated by the inhibitory protein, IκBα, in the cytoplasm (32, 33) . Multiple stimuli can rapidly induce the degradation of IκBα, resulting in translocation of the NF-κB complex to the nucleus, where it activates gene transcription (32) . The knockout of PPARα has been shown to increase NF-κB transcriptional activity via downregulation of the cytoplasmic inhibitor, IκBα (34) , whereas the activation of PPARα inhibits NF-κB transcriptional activity via the upregulation of IκBα (35) . The results of the present study showed that the systemic administration of UA in obese rats inhibited the augmentation of the expression and activity of NF-κB p65 in the spinal cord, which was associated with increased expression of IκBα in the cytoplasm. These results suggested that the restoration of spinal PPARα via systemic administration of UA prevented the exaggerated inflammatory response to peripheral inflammatory stimulation by suppressing spinal NF-κB activity. Of note, a previous study demonstrated that the systemic administration of UA attenuates the D-Galactose-induced inflammatory response in the CNS by inhibiting central NF-κB activity (36) .
In conclusion, the present study demonstrated that the systemic administration of UA inhibited the exaggerated spinal cord inflammatory response to peripheral inflammatory stimulation in HFD-induced obesity. This occurred via the restoration of the downregulated expression of spinal PPARα, thereby preventing augmented peripheral inflammation and inflammatory hyperalgesia. These observations suggested that UA may provide a potential therapeutic option for the prevention of increased inflammatory pain in obese patients.
